Registration
Advertiser Disclosure

United Therapeutics Corporation (UTHR) News: Latest Market and Industry Updates

585.95
1.4750
0.25 %
Real-time price 11:15
USD
USD
NASDAQ
Daily range
577.26 Arrow from to Icon 589.68
Weekly range
546.42 Arrow from to Icon 590.61
Live Price Short-Term Long-Term Signals Earnings Price History News
Why is United Therapeutics stock up 4% today?
  • Ashutosh Sureka
  • 22.10.2026
Why is United Therapeutics stock up 4% today?
United Therapeutics Corporation (UTHR) jumped 4.05% after management authorized a new $2 billion share repurchase program. The advance is supported by firm bullish momentum, with price action ...
#Forecast
What's behind United Therapeutics's latest 3.6% stock surge?
  • Mira Kyivska
  • 09.10.2026
What's behind United Therapeutics's latest 3.6% stock surge?
United Therapeutics Corporation (UTHR) climbed 3.65% after the family trust of Chairperson & CEO Martine A. Rothblatt exercised stock options and sold shares in a scheduled Rule 10b5-1 plan, ...
#Forecast
Liquidia faces patent ruling risk after Yutrepia launch boosts revenue
  • Aleksandra Chaikina
  • 06.10.2026
Liquidia faces patent ruling risk after Yutrepia launch boosts revenue
Liquidia is under pressure after a patent infringement ruling against its pulmonary hypertension drug Yutrepia threatens a key growth driver. The decision comes after the product helped lift ...
#Company News #Hasbro Inc
Accenture, Synopsys and United Therapeutics lead midday stock moves
  • Andrey Mastykin
  • 01.10.2026
Accenture, Synopsys and United Therapeutics lead midday stock moves
A mix of earnings beats, legal rulings and strategic announcements is driving sharp midday moves across U.S. equities. Accenture, Synopsys and United Therapeutics are among the biggest gainers, ...
#Accenture #Unilever
United Therapeutics stock rises nearly 13% as FDA accepts supplemental Tyvaso application
  • Yaroslav Dmytrenko
  • 30.09.2026
United Therapeutics stock rises nearly 13% as FDA accepts supplemental Tyvaso application
United Therapeutics Corporation (UTHR) surged 12.94% after the FDA accepted the company’s supplemental New Drug Application for nebulized Tyvaso, with expectations of regulatory review by late ...
#Forecast
U.S. midday movers highlight gains in Rogers, court-driven swings in Liquidia and United Therapeutics
  • Mira Kyivska
  • 30.09.2026
U.S. midday movers highlight gains in Rogers, court-driven swings in Liquidia and United Therapeutics
Midday trading in U.S. equities is being shaped by a mix of earnings updates, analyst calls and a patent ruling affecting several healthcare and technology names. The sharpest moves include ...
#Stocks #Rogers Communications
What's behind United Therapeutics' latest 3.8% stock pullback?
  • Oleg Tkachenko
  • 24.09.2026
What's behind United Therapeutics' latest 3.8% stock pullback?
United Therapeutics Corporation (UTHR) fell 3.84% as persistent insider selling totaling $338 million in the past three months weighed on sentiment. The decline is reinforced by the stock's ...
#Forecast
UTHR slides around 3.5% as stock trades below all major moving averages amid selling pressure
  • Andrey Mastykin
  • 02.09.2026
UTHR slides around 3.5% as stock trades below all major moving averages amid selling pressure
United Therapeutics Corporation (UTHR) declined 3.43% following renewed downside pressure, as persistent technical weakness and seller control shaped the session even as recent company updates and ...
#Forecast
Beta completes first test flights in U.S. air taxi pilot program
  • Dan Blystone
  • 10.07.2026
Beta completes first test flights in U.S. air taxi pilot program
Beta completes the first test flights under a broad U.S. government pilot program for electric vertical takeoff and landing aircraft, as the sector works through certification delays and weak ...
#USA
FDA approval for LungFX device keeps United Therapeutics stock stable
  • Emilio Ghigini
  • 01.07.2026
FDA approval for LungFX device keeps United Therapeutics stock stable
United Therapeutics (UTHR) stock is trading at $541.83 after a modest decline for the day. Price action remains within a moderate intraday range and currently sits below ...
#Forecast
Who We Are
Business Solutions
For Users
TU News
Popular Sections
Disclosures
CONTACT US
Legal
We are in Social Media
© IAFT Ltd., 2010-2026 All rights to the website are owned by IAFT Ltd.,
Registration number - HE 336186
  • Risk disclosure:

    Information on the TradersUnion.com website is for informational purposes only and does not constitute any motive or suggestion to visitors to invest money. Moreover, we hereby warn you that trading on the Forex and CFD markets is always a high risk. According to the statistics, 75-89% of customers lose the funds invested and only 11-25% of traders earn a profit. Trading in futures and options carries substantial risk of loss and is not suitable for every investor.

    That is why you should only invest money that you are prepared — or can afford — to lose at such high risks. Tradersunion.com does not provide any financial services, including investment or financial advisory services. Also, the Traders Union is not a broker and does not get money for trading in the Forex or CFD markets. Our website only provides information on brokers and the markets and helps its users to select the best brokerage company based on detailed information and objective analysis of brokers.

  • Disclaimer:

    Traders Union (TradersUnion.com) shall not be liable for the consequences of trading decisions made by the Client and for the possible loss of his capital resulting from the use of this website and information published on it.

    Forex market, CFD and cryptocurrency trading involves high risks and is not suitable for everyone. Before investing money, you need to adequately assess the level of your expertise and be aware of the risks, particularly in the context of trading with leverage. The information on this website is not intended for distribution or use by any person in any country or jurisdiction, where such distribution or use would be in violation of the local law or regulation. Any payments by Traders Union (TradersUnion.com) to the users of our website shall be legally interpreted solely as an incentive on our part for the activity on the website in the form of a deduction of a part of the advertising income; they shall not be a subject of any claims of our users or our obligations, a subject of disputes, as well as cannot be considered in relation to the services provided to users by brokers, both in fact and in their completeness and volume. The administration of the website shall not be liable for the content of user comments and reviews about the companies and shall not verify whether the authors of the reviews are indeed real clients of a specific company. All reviews, both negative and positive are published on the website without verification of their reliability; only offensive reviews that call for violence or any kind of discrimination and also reviews published from one group of IP addresses are moderated and removed. The authors of the materials shall be fully liable for the accuracy, completeness and impartiality of any information in the articles and reviews, including in the context of their use or mention of any brand names or trademarks. All mentions of the names of companies and their brands in any materials on the website shall be made in the context of communication of socially important information to the people about their activities by independent journalists, who are the authors. All evaluations and indicators on the website express the subjective opinion of the authors of the reviews (articles) and shall not be viewed as accurate statements and be a subject of disputes and claims against Traders Union.

  • Disclosure of advertisers and revenues:

    All the services on the Tradersunion.com website are free for you to use. Our team spends thousands of hours per annum researching brokers and gathering information about them to help investors all over the world to choose reliable companies and to avoid fraudsters.

    Indeed, the curating, sourcing, and organization of this process requires substantial financial investment by Tradersunion.com, which the website earns in the form of advertising payments. There are two types of advertising services on the website — direct advertising or partner (broker) participation programs. However, no services purchased by our partners shall affect the recommendations on our website, or our opinions, or ratings. Our ratings are based on our objective rating criteria and methodology; and the results are always equally and fairly applied to each broker. The work of our content authors and research groups does not involve any interaction with our advertisers and they do not have access to data concerning the amount of advertising purchased. For over 10 years we consider our independence, absolute openness, and objectivity as our main priority. Please follow the links to each of our affiliated broker’s websites. This will help Tradersunion.com to continue to provide our services to you for free.

onepercentfortheplanet.org https://gdpr.eu/ GDPR World Association of News Publishers